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Currently, there are no effective pharmaceutical treatments to reduce cognitive decline or prevent dementia. At the same time,
the global population is aging, and rates of dementia and mild cognitive impairment (MCI) are on the rise. As such, there is an
increasing interest in complementary and alternative interventions to treat or reduce the risk of cognitive decline. Depression is one
potentially modifiable risk factor for cognitive decline and dementia. Notably, exercise and yoga are two interventions known to
both reduce symptoms of depression and improve cognitive function.The current review discusses the efficacy of exercise and yoga
to ameliorate depression and thereby reduce the risk of cognitive decline and potentially prevent dementia. Potential mechanisms
of change, treatment implications, and future directions are discussed.
1. Introduction
Globally, the population is aging, and disorders associated
with cognitive decline, including dementia and mild cogni-
tive impairment (MCI), are on the rise. Research is increas-
ingly aiming to identify modifiable risk factors for cognitive
impairment. Psychological disorders such as mood and
anxiety disorders are highly prevalent in older populations
[1]. These disorders are associated with cognitive deficits,
including poor concentration, attention, and memory [2–4].
At the same time, there is growing evidence to suggest that
mood and anxiety disorders may be risk factors for cognitive
decline in later life [5]. Indeed, in older adults, dementia is
associated with similar, overlapping symptoms to depression
and delirium, and careful differential diagnosis is required to
accurately confirm that [6, 7]. In this way, amelioration of
lowmood and depression may assist in improving symptoms
of poor cognition in individuals either with or without a
diagnosis of dementia or MCI. Beyond this though, these
findings suggest that treatment and prevention of mood
disorders prior to the onset of older age and/or cognitive
decline may prevent or at least slow the development of
clinically significant deficits in cognitive function.
Recent systematic reviews and meta-analyses have con-
firmed that both mid- and late-life depression are associated
with an increased risk of dementia [8–10]. Indeed, the risk
of Alzheimer’s disease (AD) is almost doubled, and the risk
of vascular dementia (VaD) is almost tripled, if an individual
presents with clinical symptoms of depression inmid- to late-
life [8–10]. Due to the high rates of cooccurrence between
depression and dementia there is also the suggestion that
depression may be part of the dementia prodrome. Interest-
ingly, emerging evidence suggests that first presentation of
depression later in life may reflect prodromal AD, whereas
chronic or recurrent life-time depression may be associated
with long-term cerebrovascular changes that predispose an
individual towards the development of dementia, including
VaD [8, 11] and AD [10, 12]. Furthermore, the presence of
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depression in individuals showing signs of cognitive decline
(i.e., MCI) increases the risk of developing AD [13].
Depression is therefore a potentially modifiable risk
factor for cognitive decline and dementia [14, 15]. Cur-
rent first-line treatments (pharmaceutical and psychologi-
cal interventions) demonstrate moderate success; however,
nonresponse occurs in up to 50% of cases and many indi-
viduals fail to maintain long-term improvements [16–19].
Similarly, there is no cure for dementia and no treatment
to reverse cognitive decline [20]. At best, some treatments
help to alleviate certain cognitive or behavioral symptoms
[21]. This highlights the need to investigate complementary
and alternative treatments. Alternative therapies are often
appealing to individuals who have found little or no improve-
ment through standard interventions. Advantages of these
interventions include reduced cost [22] (allowing greater
access to at-risk populations and potentially producing a
more sustainable long-term intervention), fewer side-effects,
high levels of acceptability, and high congruencewith popular
culture (potentially increasing compliance). Beyond this,
complementary and alternative interventions may have the
potential to prevent future symptoms, in a way that is not
evident with pharmaceutical interventions. In this review, we
discuss the potential for two complementary and alternative
interventions, exercise and yoga, to target depression and
therefore reduce a significant risk factor for cognitive decline
and dementia.
2. Exercise to Treat Depression
Both physical activity and exercise (i.e., a subset of physical
activity that is planned, structured, and repetitive and has
physical fitness as a final or an intermediate objective [23])
have been identified as having prevention and treatment
effects on depression [24–26]. Moderate intensity, supervised
exercise programs of at least nine-week duration (trials
typically range from 8 to 16 weeks), utilising a combination
of aerobic and resistance based exercise sessions, and a group
format appear to have the greatest impact on reducing depres-
sive symptoms [27, 28]. The largest community-based trial
of exercise for major depressive disorder (MDD) involved
946 outpatients randomized to either 12 weeks of prescribed
exercise, Internet-based cognitive behavioral therapy (CBT),
or usual care consisting of brief CBT-focused therapy and
antidepressant treatment and found that supervised exercise
three times per week resulted in significantly lower depres-
sion severity compared to usual care andwas equivalent to the
Internet-CBT group [29]. These results are promising from
an implementation perspective, especially for those groups
for whom significant barriers to accessing standard clinician-
delivered CBT exist, including stigma and financial costs
associated with seeking treatment.
Nonetheless, there is ongoing debate within the scientific
literature regarding the magnitude of effect of exercise on
depression. Methodological differences between recent sys-
tematic reviews and meta-analyses [30], specifically around
(i) the argument for and against the inclusion of pragmatic
interventions such as physical activity counseling and yoga,
which many argue better reflect real world clinical practice
[31], and (ii) a large control group response (SMD −0.9)
across exercise and depression RCTs [32], have resulted in
an underreporting of the overall effect size. A 2016 meta-
analysis of 25 RCTs including people with a diagnosis of
depression and those with depressive symptoms found a large
and significant overall effect on depression after adjustment
for publication bias with an SMD of −1.11, corresponding to
an approximate 5-point reduction in the Hamilton Rating
Scale for Depression (HAM-D) and a greater than 6-point
reduction in the Beck Depression Inventory (BDI), both
of which are considered clinically significant based on the
National Institute for Health and Care Excellence (NICE)
guidelines [24, 33]. Additionally, it was found that a total
of 1,057 negative studies would be required to nullify the
significance of the main analysis, further justifying the
robustness of the analysis [24].These data are consistent with
a 2015 meta-analysis of 23 RCTs investigating the effect of
exercise on depressive symptoms of adults with neurologic
disorders including AD which found a small but significant
overall effect size of 0.28,with stronger effects of interventions
meeting recommended physical activity guidelines [34]. In
a subsequent 2016 meta-analysis, Schuch et al. reviewed the
literature relating to exercise for depression in older adults
(60 years) and found a large, significant effect of exercise on
depression across the eight included RCTs (SMD = −0.90)
[27].
In addition to large treatment effects, the preventative
role of physical activity is becoming increasingly clear. A
2013 review of 25 studies found that baseline physical activity
was negatively associated with a risk of future depression,
with evidence for an effect with even low levels of physical
activity (i.e., less than the recommended weekly total of 150
minutes [35]) [25]. Evidence for the bidirectional relation-
ship between physical activity and depression continues to
increase, with a recent longitudinal study of more than 1,000
participants showing that positive lifestyle behaviors (e.g.,
physical activity) at baseline were associated with a 22%
(RR 0.76) reduced risk of episodes of a mood disorder at
five-year follow-up [36]. These data are in line with a 2014
meta-analysis of observational studies finding that sedentary
behavior, independent of physical activity, is associated with
a significantly increased risk of depression [37]. This then
becomes a vicious cycle, as people experiencing depression
engage in significantly less physical activity compared to the
general population [38, 39].
3. Exercise to Improve Cognitive Function
Exercise is increasingly acknowledged as having a positive
effect on cognition in both the general and clinical popu-
lations, including those with depression. Evidence suggests
exercise has modest effects on aspects of cognitive per-
formance, including attention, processing speed, memory,
and executive functioning [40]. While there is emerging
evidence of a dose-response relationship between exercise
and cognition [41], even low doses of exercise appear to pro-
vide attention and visuospatial benefits for both healthy and
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depressed older adults [42, 43]. For example, improvements
in attention and inhibitory control but not working memory
have been found following a single, moderate intensity (65–
75% of estimated maximal heart rate) exercise session [43].
Subsequent analysis of data from a large study of exercise for
depression found that individuals with MDD who received
a public health guideline concordant dosage of exercise
(equivalent to 30min of moderate intensity aerobic exercise,
five or more days per week) had improved psychomotor
speed, attention, visual memory, and spatial planning at 12-
week follow-up [41].
In addition to aerobic exercise there is promising and
increasing evidence for the role of strength (resistance) train-
ing in promoting cognition among older adults. In arguably
one of the most comprehensive studies to date, Suo et al.
found that, among 100 older individuals (mean age 70.1 years)
with MCI, six months of progressive resistance training but
not computerised cognitive training significantly improved
global cognition [44]. Interestingly, the computerised cog-
nitive training program but not the exercise intervention
attenuated decline in overall memory performance. The
available evidence suggests that targeted exercise programs
are feasible, acceptable, and effective in improving aspects
of cognition among vulnerable populations including older
adults.
4. Yoga to Treat Depression
Yoga is an integrative mind-body practice that combines
physical activity (postures or asanas) with mindfulness prac-
tices (breath control (pranayama) and meditation (dhyana)),
typically performed concurrently. Several recent systematic
reviews and meta-analyses have demonstrated that yoga is
effective in ameliorating symptoms of depression across a
range of different clinical disorders, includingMDD [45–48],
posttraumatic stress disorder (PTSD) [49], stress and anxiety
[50], and schizophrenia [51], as well as at-risk samples,
such as pregnant women [52, 53], and individuals with
chronic illnesses (multiple sclerosis [54], cancer [55], and
fibromyalgia [56, 57]). Yoga also improves sleep [58], a known
transdiagnostic and risk factor for psychopathology [59, 60].
Importantly, one study demonstrated significant improve-
ments in depressed mood, well-being, and self-efficacy for
a group of older adults (65–92 years), compared to either
a control or exercise group [61]. Similarly, yoga improved
mental/emotional wellness in a small group of older adults
(66 years) [62]. These studies suggest that yoga may have
beneficial effects at any age, though longitudinal studies are
needed to determine whether there is a crucial period for
prevention of cognitive decline.
A major confound within the literature is the hetero-
geneity in methodology, including type of yoga intervention
(particularly in the ratio of asana versus pranayama), control
group, and duration and intensity of the intervention. In
particular, yoga treatment studies do not always offer dosage
equivalency to other standard treatments for depression [45].
While yoga appears to demonstrate a significant advantage
in comparison to a no treatment or passive control group,
findings are less conclusivewhen compared to active controls.
For example, one study found yoga to be less effective than
electroconvulsive therapy (ECT) but at least equivalent to
antidepressants [63]. In contrast, a recent systematic review
and meta-analysis found in favour of yoga when compared
to aerobic exercise or usual care (including group therapy,
support group, or pharmaceutical intervention, but also wait-
list control) [47]. While some studies suggest a cumulative
psychological advantage in long-termmeditators [64, 65] and
lower rate of depression remission at 9-month follow-up for
group yoga [66], overall, there is a paucity of longitudinal
follow-up studies investigating the long-term effects of yoga.
5. Yoga to Improve Cognitive Function
A recent meta-analysis concluded that yoga is associated
with overall moderate improvements in cognitive function,
particularly attention, processing speed, executive function,
and memory [67]. Acute intervention studies demonstrated
more consistent cognitive improvements and stronger effects
sizes than RCTs (𝑔 = .56 versus 𝑔 = .33, resp.). Similarly,
a recent systematic review confirmed that yoga improves
executive function in both healthy individuals and those
with chronic illnesses such as multiple sclerosis or type
2 diabetes mellitus [68]. A cross-sectional study of older
adults (>55 years) classified as long-term yoga practitioners
(>10 years) demonstrated significantly superior performance
on multiple tests of attention than an age- and education-
matched comparison group [69]. Importantly, yoga signifi-
cantly improved cognitive impairments and depressed mood
in a group of individuals with MDD [70], demonstrating
scope for treatment across multiple domains. However, as
with the literature regarding yoga interventions for mood
difficulties, major limitations exist in the literature for yoga as
a cognitive enhancing intervention. Very few studies provide
sufficient information regarding the yoga intervention and
the proportion of time spent practicing each of the major
elements (i.e., asanas, pranayama, and dhyana) [67]. At the
same time, yoga is inherently a mind-body exercise, and
arguably, it is difficult to completely disentangle the various
components (i.e., part of performing an asana correctly is
to also simultaneously and concurrently employ pranayama
and dhyana). Nonetheless, there is a need to compare yoga to
interventions that are not inherentlymind-body, that is, phys-
ical activity/exercise interventions alone, and tomindfulness-
based interventions alone. A 2010 review of 10 studies
comparing yoga to physical exercise found that yoga and
exercise were equally beneficial for physical health, but yoga
was superior to exercise for improving cognitive function
and mental health [71]. However, further research is needed,
particularly on populations with clinical disorders (either
mental or cognitive) and in older samples. Currently, there is
little regulation or standardisation in terms of recommended
dose (e.g., session duration, frequency/regularity, and long-
term duration) or type (especially in terms of variations in
emphasis on the major components) of yoga intervention.
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6. Mechanisms of Action
Many theorists suggest that the association between depres-
sion and dementia is due to a common underlying vul-
nerability factor (stress), which triggers neuroinflammation
and disruption of the hypothalamic-pituitary adrenal (HPA)
axis [72–75]. Resulting hypercortisolism may lead to neural
damage, including reduced hippocampal neurogenesis [76,
77], possibly via reductions in hippocampal brain-derived
neurotrophic factor (BDNF) [78, 79]. Hypercortisolism is
associated with depression [80], long-term impairments in
cognitive function [81], and dementia [82]. Abnormal expres-
sion of BDNF and associated reductions in hippocampal
neurogenesis are linked to depression [78, 83]. Similarly,
dysfunction of hippocampal neurogenesis [84] and reduced
BDNF [85] are both associated with increased risk for
dementia. More recently, a 38-year follow-up study found
that mid-life neuroticism is associated with an increased
risk of AD [86]. This is particularly interesting given that
current theories propose a common, nonspecific factor of
negative affect (neuroticism) as a vulnerability factor for
emotional disorders, including depression and anxiety [87,
88]. That is, either stress or neuroticism may be vulnerability
factor for depression and/or dementia. However, there is also
evidence for a direct link between the two; depression may
trigger neuroinflammation that then sensitises the brain to
other precipitants of dementia [73]. Indeed, chronic neu-
roinflammation creates a vicious cycle that may maintain
depression and increase the chances of permanent long-
term damage [74], including cognitive decline and dementia.
While further research is necessary to clarify cause and
effect relationships, particularly the extent to which a genetic
predisposition is necessary, breaking the inflammatory cycle
and/or hippocampal neurogenesis is likely to be beneficial for
preventing both depression and dementia.
Both acute and chronic responses to exercise have been
identified, including increases in atrial natriuretic peptide
(ANP), brain natriuretic peptide (BNP), copeptin, and
growth hormone, as well as chronic adaptations of copeptin
and thiobarbituric acid reactive species (TBARS) [89]. In a
recent review of the neurobiological effects of exercise on
depression, Schuch et al. [89] reported that the mechanisms
by which exercise affects depression are yet to be clearly
understood. Despite limited evidence that exercise promotes
neurogenesis and changes in inflammation biomarkers and
overall brain structure, two studies included within the
review reported evidence of an association between improve-
ments in depressive symptoms and increases in hippocampus
volume and IL-1B following exercise [89].
At the same time, a recent systematic review and meta-
analysis confirmed that yoga has a downregulating effect
on the sympathetic nervous system and the HPA axis in
response to stress, including reductions in morning cor-
tisol, blood pressure, and heart rate [48]. There is also
preliminary evidence suggesting yoga may increase BDNF
[90]. Mindfulness-based psychological therapies which have
some overlap with yoga (e.g., mindfulness-based stress
reduction (MBSR), mindfulness-based cognitive therapy
(mbCT/mCBT/MBCT)) are known to downregulate the
sympathetic nervous system and the HPA axis in response
to stress [64, 91–94] and are associated with long-term
increases in hippocampal grey matter [95]. Beyond these
anti-inflammatory effects, yoga and related activities such as
mindfulness meditation may improve mood and cognition
via increased focus, attentional awareness, and emotion reg-
ulation and/or reduced neuroticism or negative perseverative
thinking (i.e., rumination, worry) [96–100]. In this way,
yoga combines both top-down (from mind to body, through
mindfulness) and bottom-up (from body to mind, through
reduced neuroinflammation and stress response) effects that
may distinguish it from exercise, where top-down effects
are a potential side-effect versus core component. Further
research is needed to disentangle the unique versus shared
mechanisms of action between exercise and yoga.
7. Implications for Treatment
Henceforth, the challenge ahead lies in the adaptation and
translation of findings from clinical trials to person-centred
initiatives, capable of delivering appropriate exercise and
yoga interventions at a scalable level for people at risk
of or experiencing depression and/or cognitive decline.
Despite the numerous protective and treatment benefits
that physical activity and yoga may offer, effectiveness of
these interventions is overwhelmingly limited by the barriers
to being physically active that are prevalent across soci-
ety (i.e., poor motivation) and compounded among those
experiencing symptoms of depression or cognitive decline
[101]. While continued research into the mechanisms behind
the antidepressive effects of exercise or yoga is certainly
required, a focus on implementation and addressing cultural,
educational, and logistical issues within treatment services
is equally as important. While behavioral activation, a key
component of CBT that involves scheduling activities that
are pleasurable and allow opportunities for mastery [102–
104], may include some form of physical activity, this review
suggests that it is necessary. From a pragmatic perspective,
clinical psychologistsmay combine this schedulingwith posi-
tive data logs [105] and gratitude or savoring techniques [106–
110] to increase compliance. Furthermore, programs deliv-
ered by professionals such as physiotherapists and exercise
physiologists with tertiary training in exercise prescription
are associated with reduced dropout and increased moti-
vation to exercise among people with an affective disorder
[111], highlighting the importance ofmultidisciplinarymental
health teams to ensure the translation of findings into real
world, scalable programs [112–114].
8. Future Directions
Important questions remain. In particular, it is currently
unclear whether or not there are unique or combined effects
of physical activity versus mindfulness/meditation.That is, is
there something extra special about yoga (which combines
the two, within the same activity), or can either individually
exert similar positive benefits? Alternatively, is there an
external third factor (e.g., regular routine, organised social
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activity) contributing to the improvements? Currently, there
is a paucity among the literature. Very few studies have
compared yoga to either exercise or mindfulness/meditation
as short-term interventions, for either mood or cognitive
deficits. Beyond that, no studies have compared the long-term
effects of any of these interventions in the prevention of either
mood disorders or clinical cognitive deficits.
The heterogeneity of depression also needs to be ad-
dressed. Indeed, individuals require 5 of a possible 9 diagnos-
tic symptoms tomeet criteria forMDD, creating high internal
variability amongst individuals, independent of symptom
severity (see [115] for further discussion). Furthermore,
do factors such as clinical symptom severity (including
comorbidity) or clinical course (recurrent versus chronic,
age of onset, etc.) moderate the potential benefits of exercise
and/or yoga? For example, depression and anxiety are highly
comorbid [116–120], which negatively affects treatment and
recovery, quality of life, and global functioning, over and
above the effects of either disorder independently [121–123],
suggesting comorbid depression/anxiety may be quantita-
tively or qualitatively different than either disorder alone.
Studies have also demonstrated that anxiety negatively affects
cognition [2, 3, 124, 125] and that exercise [26, 46] and yoga
[46, 126] may help to ameliorate these associated cognitive
deficits. However, no study to date has teased apart the unique
effects of exercise and/or yoga on anxiety versus depression,
in relation to risk for cognitive decline. Furthermore, while
it is known that age of onset of depression plays a role in
the development of dementia [8, 10–13], it is unknown how
this interacts with treatments. For example, is there crucial or
optimal time window for intervention? Future studies should
investigate the potential benefits of exercise and yoga in the
context of clinical severity and course.
9. Conclusion
Depression is a potentially modifiable risk factor for demen-
tia. Both exercise and yoga are effective treatments for depres-
sion and cognitive decline that are also relatively easy and
cost-effective to implement. However, it is currently unclear
which components of these interventions (e.g., physical
activity, mindfulness) are necessary or sufficient to produce
change. Further research is also needed to determine whether
these interventions are capable of preventing or at least
slowing the development of clinically significant deficits in
cognitive function and, if so, the optimal timing of these
interventions.
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